TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment
Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available
10.1055/s-0045-1804783